Uveal melanoma (UM) is a rare form of melanoma with a genetics and immunology that is different from skin melanoma. Previous studies have identified genetic driver events of early stage disease when the tumor is confined to the eye. However due to lack of a clinical rationale to biopsy metastatic disease, access to tumor material to perform molecular profiling of metastases has been limited. In this study, we have characterized genomic events in UM metastases using whole-genome sequencing of fresh frozen biopsies from thirty-two patients and profiled the transcriptomes of individual tumor infiltrating lymphocytes in eight patients by single-cell sequencing. We find that 91% of the patients have metastases carrying inactivating events in the tumor suppressor BAP1 and this coincided with somatic alterations in GNAQ, GNA11, CYSLTR2, PLCB4, SF3B1 and/or CDKN2A. Mutational signature analysis revealed a rare subset of tumors with prominent signs of UV damage, associated with outlier mutational burden. We study copy number variations (CNV) and find overrepresented events, some of which were not altered in matched primary eye tumors. A focused siRNA screen identified functionally significant genes of some of the segments recurrently gained. We reintroduced a functional copy of BAP1 into a patient-derived BAP1 deficient tumor cell line and found broad transcriptomic changes of genes associated with subtype distinction and prognosis in primary UM. Lastly, our analysis of the immune microenvironments of metastases revealed a presence of tumor-reactive T cells. However, a majority expressed the immune checkpoint receptors TIM-3, LAG3 and TIGIT, and to a lesser extent PD-1. These results provide an updated view of genomic events represented in metastatic UM and immune interactions in advanced lesions.
Introduction
Uveal melanoma (UM) is a rare form of melanoma but the most common intraocular cancer 1 .
Enucleation or brachytherapy can provide good local control but in 50% of patients metastases develop, most frequently to the liver and generally with lethal outcome 1 . The genetics of UM has primarily been studied in the primary tumors of the eye, including that of the TCGA consortium 2 . Recurrent mutations in GNAQ or GNA11 are common, whereas mutations in PLCB4 and CYSLTR2, downstream and upstream of GNAQ/11, are seen in occasional cases [3] [4] [5] [6] . These driver mutations are all mutually exclusive. Additional recurrent mutations have been found in EIF1AX, SF3B1 and BAP1, where the latter connotes poor prognosis and development of metastatic disease 7, 8 . The development of metastatic UM can also be predicted using gene expression analyses, where Class 1 tumors have an excellent prognosis whereas Class 2 have a very poor prognosis, in a close to binary manner 9 .
Patients with UM metastases are not predicted to respond to the same targeted therapies as patients with cutaneous mutations since UM does not have BRAF mutations.
Moreover, retrospective analyses of outcome following the use of immune checkpoint inhibitors have demonstrated poor response rates at multiple centers 10 . At our center, we are using isolated hepatic perfusion with melphalan to treat patients with liver metastases of UM.
Retrospective analyses have suggested a survival benefit of this surgical method but this is now being challenged in a prospective randomized phase 3 trial (the SCANDIUM trial) 11 .
Notably, during the surgical procedure leading to the perfusion treatment, there are possibilities of procuring fresh biopsies for the generation of PDX models, TIL cultures and for genomics studies of metastases ( Fig. 1a) . Here we describe a profiling of thirty-two metastatic UM tumors using whole-genome sequencing and we characterize infiltrating lymphocytes, providing molecular insight into the genomic events and immunogenetics driving late-stage UM.
Results

Recurrently mutated genes in UM metastases
Thirty-two metastases of UM, six subcutaneous and 26 from the liver (Table S1), were collected and subjected to whole-genome sequencing (WGS) and 26 of them to poly-A+ RNA sequencing. Twenty-eight of the tumors were pathologically designated as originating from the choroid, one in the ciliary body and one in the iris, while two cases were ambiguous.
All liver metastases came from patients that were untreated at the time of biopsy and 24 of them had been enrolled in the SCANDIUM phase III trial. All cutaneous biopsies except one came from patients previously treated with chemotherapy (IHP, dacarbazine and/or taxanes).
Variant calling with MuTect 2 12 revealed mutations in BAP1, GNA11, GNAQ, SF3B1, CYSLTR2, and PLCB4 (Fig. 1b, S1 and Table S2 ), which are recurrently altered in UM [2] [3] [4] 7 . We discovered no mutations in EIF1AX, which is associated with a good prognosis 2, 7 . In all, 29/32 (91%) of metastases were found to harbor BAP1 mutations. These were paired with loss of chromosome 3 the vast majority of cases ( Fig. 1b) . Notably, BAP1
was also the subject of alterations not detected by standard variant calling, including one large deletion spanning the first three exons. In another case, one intronic event far from the nearest splice site was associated with novel splicing events at the point of the mutation and intron retention (Fig. 1c) . A third tumor contained a 48 bp fully intronic homozygous deletion that again did not occur at a splice site, but associated with mis-splicing and intron retention clearly tied to the event (Fig. 1d) . These two alterations most likely created new intronic splice sites. A previous study has described a mutation that activates a cryptic splice site within an exon in BAP1 13 . To our knowledge no cases have been described for de novo splice-site-generating intronic mutations in UM; only cases that disrupt canonical splice sites at the exon-intron boundary 14 . Since BAP1 loss predicts metastasis 15 , this highlights the need to also investigate intronic non-splice site mutations as candidates for loss-of-function events, which exome 2 or targeted 16 sequencing may not be sufficient to reveal.
Among the three patients where BAP1 mutations could not be established, two had SF3B1 mutations. We also detected mutations in SF3B1 that occurred outside the common hotspots K666 or R625. These were K700E, I955S and an in-frame deletion at V577. The first has to our knowledge not been described in UM, but is frequent in other cancer types, including breast cancer 17 , chronic lymphocytic leukemia 18 and pancreatic adenocarcinoma 19 . Some SF3B1 mutations also co-occurred in tumors with BAP1 mutations, illustrating that mutual exclusivity between these events is not perfect 2,3 .
In the third tumor without BAP1 mutation, we did not discover mutations in either SF3B1 or EIF1AX. This tumor (UM28) was also the only one inferred to be tetraploid ( Fig. S2b) , and had frequent wide copy number losses, affecting chromosomes 1p, 3, 4q, 6q, 8p, 9, 11, 14 and 16 . Mutated genes in these regions included YEATS2 and ZMAT3 on chromosome 3 and AKT1 on chromosome 14. This sample also displayed the second highest levels of PRAME expression, which has been independently associated with metastasis 20 .
In addition, we found two metastases with mutations in the tumor suppressor TET2, in one case leading to a stop-gain. A third tumor had a frame-shift deletion in TET1. TET1 and TET2 exert epigenetic control via DNA demethylation 21, 22 . Some metastases also had mutations in genes that interact with BAP1, including ASXL2 and FOXK2 23 (Table S2) . 5 
Mutational signature of UV damage in UM
The causes that underlie UM are to date largely unknown, and despite risk factors implying a potential role for UV radiation, no clear evidence has emerged to date and the field is divided on whether this can be a driving factor 1, 4, [24] [25] [26] [27] [28] . The pattern of trinucleotide substitutions across the genome can be informative about underlying mutational processes. Therefore, we estimated the relative contributions of established mutational signatures 29 to the total exonic mutational burden in the tumors.
Consistent with previous observations 4 , the dominating signatures were S3, S5 (COSMIC nomenclature), and to a lesser extent S16. S3 has been associated with defective DNA double-stranded break repair, whereas S5 is termed "clock-like" and associates with aging 29, 30 (Fig. 1e ). However, one tumor had a distinctly different profile, dominated by contributions from S7 (about 63%), with a bias towards the untranscribed strand (q < 0.05, Poisson test), more closely resembling cutaneous melanomas sequenced concurrently ( Fig.   1e-f ). S7 is known to arise as a consequence of UV radiation-induced damage 29 . We could exclude a mix-up from the presence of the same GNA11 Q209L mutation and BAP1 frameshift deletion in RNA, together with transcriptomic classification against ~10000 tumors from TCGA ( Fig. S3a-c) .
We hypothesized that this unexpected signature could be explained due to the tumor having originated in the iris ( Fig. S3d-e ), a site from which only 3-5% of cases arise 31 , compatible with an absence of iris melanomas and UV evidence in the TCGA UM cohort 2 . To confirm this, we managed to obtain a second iris UM sample from a patient without metastasis, which again revealed a prominent a UV pattern ( Fig. 1g) . Thus, although rare, UM can evidently be induced by UV damage if manifest in the iris.
Copy number changes overrepresented among metastases
UM is characterized by highly recurrent copy number aberrations affecting entire chromosome arms 2 . All metastases had gain of chromosome 8q, known to co-occur with monosomy 3 in poor prognosis tumors 26, 32, 33 (Fig. 2a) . A number of arm-level changes were also significantly overrepresented in the metastatic tumors compared to tumors studied by TCGA (Fisher's exact test, q < 0.05). These were loss of 17p and 6q, as well as gain of 8q and 5p gain ( Fig. 2a-b , Table S3 ). Loss of chromosome 3 was close to significance at q < 0.094. Previous studies have also found loss of 6q and 8p to be overrepresented in metastatic tumors 26, 32 . Sequencing of matched primary tumors for UM16 and UM24 showed that 8q gain and loss of 3 was present already in the primaries in both cases ( Fig. 2c) .
However, gain of 5p in UM16 and loss of 6q in UM24 were later events only present in the 6 respective metastases. Overall, genomic losses tended to be more frequent in these metastases than observed in TCGA tumors.
Focal events were very rare. Notably, however, we discovered somatic focal deletions affecting CDKN2A and the nearby gene MTAP in two samples ( Fig. 2d, Fig. S4 ).
CDKN2A encodes the tumor suppressors p16 INK4a and p14 ARF and is commonly deleted in cutaneous melanoma 34 . The deletions here were homozygous and hemizygous respectively.
While CDKN2A expression was still present in the hemizygous case, a subsequent patientderived xenograft (PDX) model established from this tumor showed full loss of expression, even extending to other nearby genes ( Fig. 2e, Fig. S5 ). This suggests that either a preexisting clone with a homozygous deletion or a second loss event was selected for as the tumor established itself in this new environment, supporting CDKN2A loss as a late event that may be relevant in the metastatic setting.
Survey of genes in recurrent arm-level copy number events that may influence tumor behavior
To understand how the recurrent chromosomal events in UM affect the transcriptome and to rank genes by a potential to influence tumor behavior, we searched for consistent correlations between the copy number of each gene affected and its expression in this dataset and TCGA UM, and ordered them by their degree of known protein-protein interactions from the HPRD database, followed by association with survival. The top candidates per region are shown in (Fig. 2f , Table S4 ). An analysis using the "chemical and genetic perturbations" collection in MSigDB showed that regions of gain were enriched for the category "uveal melanoma class II up" (q < 1.84*10 -19 ), whereas regions of loss were enriched for "uveal melanoma class II down" 35 (q < 3.15*10 -17 ). The class II transcriptional subtype is one of the two major subdivisions of UM, strongly associated with metastasis 35 . A Reactome enrichment analysis revealed processes that included cell cycle progression, chromosome maintenance, immune signaling and hemostasis ( Fig. 2g , Table S5 ).
Top ranked genes in loss regions included CASP9, an early activator of apoptosis 36 and the aforementioned CDKN2A. Candidates in gain regions included MAPK14 (p38α), a kinase that operates at the intersection of cell cycle progression, stress signaling, immune responses and differentiation [37] [38] [39] [40] , and the very recently proposed UM oncogene PTK2 (FAK) 41 , a negative regulator of cell detachment-initiated apoptosis (anoikis) 42, 43 . A small RNAi screen, directed against a list of genes selected based on gain candidates, in a cell line derived from the UM22 tumor demonstrated that 8/12 siRNA pools negatively affected proliferation (cell count) or viability (ATP production) to a similar or higher level than an siRNA against GNAQ (Fig. 2h) . Thus, these recurrent arm-level copy number changes contribute to shaping the transcriptomic subtypes of UM and regulate genes that may conceivably contribute a fitness advantage.
BAP1 loss contributes to a transcriptomic shift towards the metastatic class II subtype and up-regulates TIM-3 and TIGIT immune checkpoint ligands
We next asked to what extent BAP1 loss could influence the transcriptome of metastatic UM.
For this purpose, we used the UM22 cell line, which had been established from one of the metastases grown as a PDX, which had a homozygous frame-shift deletion in BAP1 (Fig.   S5) . A functional copy of BAP1 was introduced using a retroviral vector and RNA-seq performed on this and an empty vector control sample ( Fig. 3a) . RNA-seq alignments showed successful integration of the wild-type BAP1 allele ( Fig. 3b) . A differential expression analysis between the two conditions revealed a large transcriptomic response, with 518 genes downregulated and 990 upregulated at an absolute log 2 fold change > 1 and q < 0.05 ( Fig. 3c , Table S6 ). SLC7A11, identified by Zhang et al. as a mediator of ferroptosissuppressive effects of BAP1 44 , was significant albeit not as strongly regulated (log 2 fold change = -0.82, q = 5.42*10 -19 ). Pathways enriched among downregulated genes upon reintroduction included GPCR signaling, neurotransmitter receptor transmission, interferon alpha/beta signaling and chemokine activity. Upregulated pathways most prominently included post-transcriptional and translational mechanisms ( Fig. 3d) .
Notably, we observed significant regulation of nine out of 12 genes used as discriminating features in a classifier that distinguishes between the high-risk class II versus class I subtypes 45, 46 , some of which are melanocyte lineage markers and a few of which have also been found compatibly regulated upon silencing 8 (Fig. 3c) . These genes were all expressed in the inverse fashion expected for class II tumors, with CDH1, ECM1 and HTR2B decreasing upon BAP1 reintroduction and LMCD1, LTA4H, MTUS1, ROBO1, SATB1 and FXR1 increasing. This was confirmed with additional RT-qPCR measurements for all genes but FXR1 (Fig. 3e) .
To investigate whether this trend was limited to these few discriminating genes or representative of a broader transcriptomic shift towards the class I subtype, we performed a gene set enrichment analysis on the whole list of differentially expressed genes using the "chemical and genetic perturbations" collection from MSigDB 47 . We found the "uveal melanoma class II down" gene signature 35 to be significantly enriched among upregulated genes (q < 0.00031), and "uveal melanoma class II up" to be enriched among downregulated genes (q < 0.012), showing that this trend is indeed broader (Fig. 3f, Table S7 ). This shift towards the class I subtype upon BAP1 reintroduction implies that the inverse drives the cells towards the metastatic class II transcriptional subtype, which characteristically has BAP1 alterations. 8 Beyond this, BAP1 restoration also downregulated the TIM-3 immune checkpoint ligands HMGB1 and PTDSS1 as well as the TIGIT and CD96 ligands PVR and PVRL2, implying higher expression levels in BAP1-deficient UM cells ( Fig. 3g , Table S6 ).
T cells from UM metastases recognize tumor antigens and predominantly express the checkpoint receptors LAG3, TIM-3 and TIGIT
Having observed the regulation of checkpoint proteins in UM cells, we next investigated the phenotypes of tumor-infiltrating lymphocytes (TILs) isolated from metastases. Despite the generally poor immunogenicity of UM, we could confirm the presence of melanoma-specific TILs in a subset of patients ( Fig. 4a) . This included the UV-associated iris tumor, which was also predicted to have the highest neoantigen load ( Fig. 4a and Fig. S6 ). More detailed flow cytometry of cryopreserved single cell preparations of tumors revealed PD-1 + CD39 + cells present in high fractions of CD8+ T cells in a subset of samples ( Fig. 4b-c , gating strategy in We therefore performed single-cell RNA and T cell receptor (TCR) sequencing of TILs from these eight tumors for a more comprehensive view.
Inference of cellular subtypes by correlation to pure PBMC subsets 49 revealed similar proportions of CD8+ and CD4+ subsets as observed by flow cytometry (Fig. 4b-d and 
Discussion
Metastatic UM currently entails a very poor outcome due to the lack of effective treatment options 15 . Genetics of the primary disease confined to the eye has already been investigated in several hallmark studies 2-4,7-9 . However, only a few metastatic samples have been sequenced with exome or whole-genome sequencing and our study has the largest sample cohort sequenced to date with whole-genome sequencing. A history of primary uveal melanoma and lack of therapeutic efficacy of surgery makes biopsy and surgical removal of samples not clinically meaningful. By obtaining biopsies of liver metastases from patients in the SCANDIUM trial or cutaneous metastases of UM, we have been uniquely positioned to focus on the metastatic disease by both analyzing fresh frozen material by genomics as well as generating PDX, cell lines and TIL cultures for transciptomics analyses.
The key event to metastasis in UM is loss of the tumor suppressor BAP1 8 .
Compatible with this, we observed BAP1 alterations in 91% of the metastases. Two of these altered splicing via intronic events outside of canonical splice regions, via creation of new intronic splice sites. This illustrates special cases that exome sequencing may not be sufficient for detecting, and which have high prognostic value.
We furthermore find that out of two tumors studied of the iris subtype, both had mutational spectra associated with UV-induced damage. Mutational signatures of UV damage in UM have not previously been reported and a consensus of UV-involvement in UM has not been reached by previous epidemiological studies. While iris UM is rare, the metastasis studied here had much higher than average mutation load, and predicted number of neoantigens. This could potentially render such tumors suitable for immunotherapy, which otherwise lacks efficacy in UM. Interestingly, the iris UM metastasis concerned here also harbored T cells recognizing MART-1.
Several broad copy number events were found to be more frequent in the metastases studied compared to primary tumors from TCGA, including losses of 17p loss and 6q, as well as gains of 8q and 5p. Notably, 8q gain was present in every metastasis. By sequencing matched primary tumors for two cases, we could establish that in one of the tumors 5p gain and 17p loss had arisen during metastasis, and in the other case 6q loss. Furthermore, two tumors had focal deletions of CDKN2A, an event that may have a larger relevance in the metastatic setting, as it has not been detected in recent large-scale studies of primary UM tumors 2-4,26,28 .
We additionally mapped out genes with correlations between expression and arm-level copy number changes in both this dataset and that of TCGA and ranked them by their degree of protein-protein interactions and any associations with survival present to gain an understanding for central processes affected and potential targets. We found several interesting candidates, including the recently proposed UM oncogene PTK2 41 , MAPK14, the apoptosis mediator CASP9 36 , as well as CDKN2A to be first-ranked candidates in 8q gain, 6p gain, 1p loss and 9p loss, respectively. We performed an siRNA knockdown experiment against selected genes and found proliferation and viability decreases to be the consequence when targeting the majority of those. In addition, we found expression changes mediated by loss events to be enriched for genes generally downregulated in poor-prognosis tumors and gain events enriched for genes upregulated in poor-prognosis tumors, showing that these broad events contribute to shaping the distinct transcriptomes of the two subtypes.
To increase our understanding for how these transcriptomic subtypes are established, we investigated the contribution from BAP1 loss by reintroducing a functional allele into a cell line established from one of these metastases. We found that genes upregulated in cases with the functional gene where enriched for those that are lowly expressed in the poor-prognosis class II subtype, and vice versa. In essence, reintroduction indicated a reversal of the transcriptomic subtype. Notably, also immune checkpoint ligands where found regulated by BAP1. Of potential importance was the downregulation of TIM-3 and TIGIT ligands in the cases with functional BAP1, indicating a potential upregulation on BAP1 loss that may have consequences for tumor-immune interactions.
We profiled the transcriptomes of tumor-infiltrating lymphocytes isolated from Collectively, these results highlight that exome sequencing may not be sufficient to detect BAP1 loss, the most significant event in UM metastasis, that UV damage underlies an important mutational process in the iris subtype and that recurrent copy number aberrations cooperate with BAP1 loss to shape the transcriptome of the metastatic subtype.
We also describe immune-profiles of T cells present in metastases that indicate tumor recognition, but exhaustion with predominant activation of checkpoints that are not targeted by current immunotherapies.
Methods
Processing of tumor biopsies
The patients received oral and written information and signed the informed consent according to the ethical approval at the Regional ethical review board (#289-12 and # 144-13). Biopsies were either extracted from subcutaneous metastases or from liver metastases, during the procedure of isolated hepatic perfusion in the SCANDIUM trial for those participating in it. Tumor biopsies were divided into pieces that were snap-frozen or minced 11 and used for cryopreservation or tumor-infiltrating lymphocyte cultures. Primary eye tumors were formalin fixed and paraffin embedded (FFPE) in blocks at St Erik's Eye Hospital's pathology biobank.
Sequencing DNA and RNA from fresh frozen biopsies, blood and tumor-infiltrating lymphocytes were extracted using the AllPrep DNA/RNA kit (Qiagen). Primary eye tumors were sectioned and processed using an FFPE DNA kit (Qiagen). Libraries were made using Illumina TruSeq kit and sequenced on HiSeq2500 instruments at SciLifeLabs in Stockholm or on a NovaSeq at GeneCore SU in Gothenburg. Exome sequencing libraries were prepared with the Nextseq500 Kit HighOutput v2 and sequenced with Nextseq500. 
Preprocessing of DNA sequencing data
Mutational signature analysis
To determine mutation spectra, all exonic somatic mutations (including synonymous) not present in any population variant resource were converted into a 96-trinucleotide mutation frequency matrix using the function "mut_matrix" (parameter: ref_genome = "Bsgenome.Hsapiens.UCSC.hg19", excluding the sex chromosomes) from the R package 
HLA-genotyping
HLA genotyping was performed using polysolver (version 1.0) 59 on whole-genome sequencing data, with the parameters "Unknown 0 hg19 STDFQ". 
Neoantigen prediction
Differential expression analysis
RNA-seq data was aligned and quantified as described. Differential expression was assessed using DESeq2, with the parameter "alpha=0.05". Genes with q-values below 0.05 were considered statistically significant. Gene set enrichment analysis was carried out with the R package "fgsea" 61 , with gene sets obtained from MSigDB 47 , using parameters "minSize=0", "maxSize=10000" and "nperm=10 7 ". Categories with q < 0.05 were considered statistically significant.
RT-qPCR validation of genes identified from differential expression analysis
RNA was extracted from the indicated cell lines with Nucleospin RNA II kit (Macherey-Nagel), and converted to cDNA using iScript cDNA synthesis kit (Bio-Rad 
Transcriptome comparison with tumors from TCGA
RNA sequencing data for 9,583 tumors from 32 cancer types were downloaded from the cgHub repository on December 18, 2015, and aligned to the hg19 human genome assembly, 14 excluding alternative haplotype regions, with hisat 62 0.1.6-beta (parameters: "--no-mixed -no-discordant --no-unal --known-splicesite-infile"), using splice junctions defined in the GENCODE (version 19) reference human genome annotation. Gene read counts were derived with htseq-count 54 (parameters: "-m intersection-strict -s no"). RPKM normalized values were calculated, taking into account the max mature transcript length of each gene and using robust size factors as previously described for the DESeq method 63 . For the correlation analysis, reads from our own sample was realigned and read counts requantified and normalized using the same methods described for TCGA data. However, standard read depth-based size factors were used for the RPKM normalization of this sample. Pairwise Spearman correlation coefficients were then calculated between our sample and each TCGA sample, with respect to all coding genes (using the function "corr" in MATLAB R2018a). For t-distributed stochastic neighbor embedding (t-SNE) analysis, log 2 transformed (pseudocount of 1 added) expression values of all coding genes were used, together with the "Rtsne" function from the "Rtsne" R package 64 . A separate classification was performed using a 6nearest neighbor approach based on Spearman correlations, as previously described 65 . 
Copy number segmentation and purity estimation
Associations between broad copy number changes and metastatic or primary tumors
Segmented copy number data from TCGA primary tumors were downloaded from GDC Data Portal (accessed on 6 October 2017). Copy number changes with an absolute log 2 ratio relative to diploid chromosomes less than 0.2 and with width less than 10 6 base pairs were filtered out from both TCGA UMs and our tumors. The general events to test were defined as those where a contiguous altered region spanning all events in all metastasis samples were present that had a width of at least 10 6 base pairs, and which occurred in at least 5% of samples in either dataset, to avoid events that were unlikely to be relevant to selection.
Changes of same direction (loss or gain) affecting each region were then assessed for association with each of the two datasets using Fisher's exact test (two-tailed) using the function "fisher.test" in R 3.5.0. Since the resulting contiguous regions practically spanned the entire length of each affected chromosome arm, with the exception of chromosome 3, which spanned the entire chromosome, one test was performed per gain or loss event of each such arm. p-values were corrected for multiple testing using the Benjamini-Hochberg method.
Ranking of genes in broad copy number aberrations
RNA-seq data for the TCGA UVM dataset (n = 80) were downloaded using the TCGAbiolinks R package 67 , with parameters "project = 'TCGA-UVM', data.category = 'Transcriptome Profiling', data.type = 'Gene Expression Quantification', workflow.type = 'HTSeq -Counts'".
Read counts were normalized using the "rpkm" method from the "edgeR" package ("log=FALSE, prior.count=1"), with gene lengths chosen as the maximum transcript length obtained via biomaRt and the "ensembl" database. Segmented copy number profiles for each sample were downloaded from the GDC data portal. The copy number status of each gene was calculated by choosing the maximal absolute log 2 ratio among segments spanning the gene. Genes with both copy number and gene expression values assigned were retained.
To focus on genomic regions subject to copy number changes recurrent enough to indicate selection, TCGA GISTIC results 2 were used (obtained from gdac.broadinstitute.org, accessed 4 July 2017). Recurrent broad copy number changes with q-values < 0.05 were retained. To focus on genes that were altered at relevant frequencies and more likely to be part any minimal region of overlap, genes with an absolute log 2 copy number ratio < 0.2 were filtered out and only genes with an alteration frequency in the upper third quartile per chromosome arm event were retained. The third quartile was chosen, rather than a stricter threshold, since some regions may be subject to low-frequency focal events of a random or artifactual nature.
To find genes altered in expression in tandem with the copy number changes, linear regression between copy number and expression was performed, adjusting for tumor purity estimates obtained from Zheng et al. 68 . Genes with too low expression variance to test were removed (defined as those for which regression failed to converge). Univariate survival tests with Cox regression (the "coxph" function from the "survival" R package 69 ) were then carried out against clinical data downloaded using TCGAbiolinks 67 , using the variables "vital_status", "days_to_death" and "days_to_last_follow_up".
Segmented copy number values from our metastasis samples were mapped to gene names as described above and converted to log 2 ratios. Values of zero prior to transformation were set to the lowest observed non-zero copy number value. Gene expression values for the metastasis dataset were normalized with RPKM as described above and batch corrected using the "removeBatchEffect" function of the "limma" R package 70 . Genes with values in both the copy number and gene expression dataset as well as preserved after the filtering on the TCGA data were retained. Associations between gene expression and copy number status were assessed as for the TCGA dataset, considering sample purity. p-values from associations in the TCGA data and metastasis dataset were combined using Fisher's method and FDR adjusted using the Benjamini-Hochberg method.
Candidates with q-values < 0.05, an independent raw p-value of less than 0.05 in each dataset and correlations consistent with the direction of the assessed copy number event were retained. Candidates in regions with more samples harboring gains than losses were retained as candidates of gains and vice versa.
To assess the extent to which a given gene may have a wider impact on cellular behavior, manually curated protein-protein interactions with experimental evidence defined in the Human Protein Reference Database (HPRD) 71 were used. The database was accessed using the "iRefR" R package 72 and node degrees calculated using the "degree" function in the "igraph" package 73 . The candidates were then ranked by the number of HPRD 
Single-cell RNA-seq analysis of immune infiltrates
Small pieces of tumor biopsies were cultured for two weeks in RPMI medium containing 10% human serum and 6000 U/ml IL-2. Young TIL (yTIL) cultures were then cryopreserved before use. Two days before performing the single cell experiments, yTIL cultures were thawed.
Cells were counted and 7 000 cells were injected into a single cell library preparation instrument (10x Genomics). The steps following were performed using the Single Cell V(D)J kit according to the kit description (10x Genomics). V(D)J libraries were sequenced on a MiSeq instrument (Illumina) whereas the gene expression libraries were run on a NextSeq (Illumina). Single-cell transcriptomics data were aligned against the hg38 reference genome and preprocessed using the Cellranger pipeline provided by 10x Genomics. Expression levels were estimated using the Cellranger "count" function, with default parameters. TCR chain assembly was also performed using the Cellranger pipeline, using default parameters.
t-SNE maps for each sample were generated using the SingleR R package (version 1.0) and cell types were inferred using the approach described by Zheng et al. 49 , with two modifications: correction of a code error that misclassified some CD4+ cells and reclassification of cells classified as memory CD4+ cells not expressing CD4 but CD8 as the closest matching non-CD4+ cell type. Doublet cells were defined as those expressing more than one alpha or beta chain and those that were classified as doublets by the tool DoubletFinder 74 (default parameters). TCR clonotype diversity was assessed for CD8+ cells using clonotype frequency and the "diversity" function (type = "e") from the "diverse" R package 75 
Flow cytometry
Single cell suspensions from cryopreserved tumor biopsies and yTILs were surface stained for 30 minutes in RT. The following antibodies were used for surface staining: CD3 (HIT3a), CD4 (A161A1), CD8 (HIT8a), CD45 (2D1), CD69 (FN50), CTLA-4 (BNI13), PD-1 (EH12.H7),
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TIGIT (A15153G) and TIM-3 (F38-2E2) from BioLegend and CD39 (eBioA1) from eBioscience. For detection of melanoma antigen specific CD8 T cells, cells were surface stained for 45 min in 37°C using Melanoma Dextramer Collection 1 kit from Immudex. Dead cells were excluded from the analysis using Live/Dead Aqua (Invitrogen). Flow cytometry data was acquired using BD Accuri C6 (BD Biosciences), BD LSRFortessa X-20 (BD Biosciences) or BD FACSARIA FUSION (BD Biosiences) and analysed using FlowJo software (FlowJo LLC). The gating strategy is shown in Fig. S6 .
Ethics
The patients received oral and written information and signed the informed consent agreement according to the ethical approval at the Regional ethical review board (#289-12
and # 144-13). Animal handling: Regional animal ethics committee of Gothenburg approval #36-2014. MSigDB "chemical an genetic perturbation" category, with results from the two sets discriminating between class I and II subtypes shown 35, 47 . g) Downregulation of ligands to the immune checkpoint receptors TIM-3, TIGIT and CD96 upon BAP1 reintroduction. 
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